Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	DDIT4	Synonyms	Dig2, REDD-1, REDD1	Type of gene	protein-coding
Chromosome	10	Map location	10q22.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	DNA damage inducible transcript 4

GTO ID	GTC1299
Trial ID	NCT00713518
Disease	Age-Related Macular Degeneration
Altered gene	DDIT4
Therapeutic/Target gene	Target gene
Therapy	siRNA
Treatment	PF-04523655\|REDD14NP\|PF-655
Co-treatment	ranibizumab
Phase	Phase2
Recruitment status	Completed
Title	Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study)
Year	2009
Country	Austria\|Denmark\|China\|India\|Israel\|Korea,Republic of\|Philippines\|Spain\|Turkey\|United States
Company sponsor	Quark Pharmaceuticals
Other ID(s)	B0451001

Cohort1: ranibizumab

Administration route	intravitreal injection
Dosage	ranibizumab, 0.5 mg, every 4 weeks from baseline to Week 12
Age	Adult, Older_Adult

Cohort2: ranibizumab_PF-04523655_dose level 2_every 2 weeks

Administration route	intravitreal injection
Dosage	3 mg, every 2 weeks from Week 4 to Week 12
Age	Adult, Older_Adult

Cohort3: ranibizumab_PF-04523655_dose level 1

Cohort4: ranibizumab_PF-04523655_dose level 2_every 4 weeks

Administration route	intravitreal injection
Dosage	3 mg, every 4 weeks from Week 4 to Week 12
Age	Adult, Older_Adult

Cohort5: ranibizumab_PF-04523655_dose level 1_combination from baseline to Week 12

Administration route	intravitreal injection
Dosage	1 mg, every 4 weeks from baseline to Week 12
Age	Adult, Older_Adult

Overview of Knowledge Graph